OFMOM NEWSROOM
Mamiai and Yitaning Boast their Brand Excellence in 2023 CHEO
In 2023, the 16th CHEO(China Health Ecology Organization) was successfully held in Boao, Hainan
from August 9th to 14th, with the theme of “Reshape the Industry with Dual
Synergy, Open a New Era of Individual Health.”
The symposium attracted over 8,000 industry
experts from diverse sectors, including government agencies, domestic and
foreign mainstream brand industries, commercial & retail companies, novel
drug companies, biotechnology firms, CXO leadership, digital technology
innovators, medical and health service institutions, domestic and foreign
capital powerhouses, commercial insurance institutions, prominent media
outlets. They discussed how to fulfill the interaction of ecological value with
new developmental pathways. Additionally, the 2023 Health Industry Brand List
was grandly announced.
Drawing upon data from Sinohealth, brands
were meticulously evaluated according to four critical dimensions: product
value, profit expectations, market value, and user praise. Mamiai and Yitaning,
products from Beijing Hanmi Pharm were once again nominated on the 2023 Brand
List and won the Gold Award. This recognition serves as a testament to their
enduring excellence, being consistently on the list over multiple years. In
doing so, they fortify Beijing Hanmi’s leading position in the field of
children’s medicine and health.
Mamiai®, intestinal health medicines
for children, and Yitanjing®, cough medicines for children, have become one of
the must-have home remedies for many Chinese families. Moreover, Beijing Hanmi
Pharm has been endeavoring to strengthen its brand impact in the field of
pediatric health. Notably, Aipufen® (ibuprofen syrup), antipyretic medicine for
children, Tonglang® (paracetamol syrup), antipyretic and analgesic medicine for
children, Narping® (compound paracetamol syrup), cold medicine for children,
and Xiandale® (levocetirizine hydrochloride syrup), allergy medicine for
children, have also expanded their share of the children’s medicine market.
Furthermore, Beijing Hanmi Pharm has actively
pursued the research and development of new drugs. In recent years, they’ve
launched groundbreaking products, including Yianping® (ambroxol hydrochloride
solution for inhalation) and the first-of-its-kind single-tablet compound of
amlodipine and losartan potassium in China—Meiyaping®. These innovations have
ushered in a new era within the chronic disease market. It is worth noting that
Beijing Hanmi Pharm consistently spends the largest investments in research and
development of new drugs and technologies among various pharmaceutical
companies, and this investment is increasing year by year.
It is expected that Beijing Hanmi Pharm will continue to promote the sustainable development of the health industry and maintain its leading position in the children’s health industry.